XML 362 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - COP ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net income before income tax $ 3,137,904 $ 3,487,550 $ 6,274,371
Reconciliation of net income before taxes and net cash (used) provided by operating activities:      
Depreciation of tangible assets and right-of-use assets 588,288 557,062 559,875
Amortization of intangible assets 686,337 594,109 530,625
Impairment losses on loans and other accounts receivable 4,826,291 4,802,074 3,179,476
Net interest income (7,267,599) (6,286,974) (7,738,637)
Accrued dividends (148,452) (126,274) (119,888)
Net gains on sales of non-current assets held for sale (21,498) (47,994) (9,687)
Gain on sale of property plant and equipment for own-use (75,508) (344,742) (140,229)
Loss on sale of investment property 14,398 22,177 17,305
Gain on biological assets (9,377) (10,467) (13,041)
Valuations and interest from concession agreements (2,850,244) (3,916,465) (5,136,704)
Foreign exchange losses (gains) 454,818 (2,253,925) 1,825,718
Profit of equity accounted on investments in associates and joint ventures (378,396) (371,397) (372,777)
Net (gains) or losses on fair value adjustments of:      
Derivatives (415,640) 2,581,132 (1,529,855)
Non-current assets held for sale 4,662 268 76
Investment properties (35,841) (84,958) (55,930)
Biological assets (7,589) (18,601) (56,859)
Changes in operating assets and liabilities:      
Trading assets (5,566,417) (2,764,761) 545,497
Other accounts receivable (719,903) (975,734) (2,376,815)
Derivatives 238,494 (2,091,326) 1,379,945
Other assets (136,824) (78,251) 121,837
Other liabilities and provisions 1,085,770 1,434,088 462,871
Employee benefits 49,199 (27,517) 7,928
Loans (13,964,962) (7,600,446) (27,840,725)
Customer deposits 14,823,718 15,352,172 17,835,153
Interbank borrowings and overnight funds 3,326,240 5,881,960 (1,352,653)
Borrowings from banks and others (1,213,612) (4,105,107) 9,127,800
Interest received 28,017,616 26,104,288 16,944,928
Interest paid (21,411,250) (21,529,719) (10,608,415)
Interest paid on leases (239,745) (202,362) (146,275)
Income tax paid (2,008,589) (1,974,359) (1,537,039)
Net cash provided (used in) operating activities 782,289 6,005,501 (222,124)
Cash flows from investing activities:      
Acquisition of property, plant and equipment for own use and operating lease (636,099) (589,071) (519,368)
Acquisition of investment property (793) (163) (2,266)
Additions of cost of biological assets (26,572) (26,118) (28,368)
Capitalization and payments in concession contracts 305,686 853,778 452,612
Additions of others intangibles assets (658,589) (683,457) (598,177)
Acquisition of investments at FVOCI (15,351,132) (24,353,596) (21,008,926)
Proceeds from sale of investments at FVOCI 12,048,278 25,675,840 23,492,758
Proceeds from sale of own property and equipment 78,499 76,699 72,991
Proceeds from sale of investment properties 66,358 111,542 76,306
Proceeds from sale of biological assets 35,871 37,144 40,624
Proceeds from sale of non-current assets held for sale 49,699 61,652 41,635
Purchases of financial assets at amortized cost (7,822,526) (8,016,108) (6,914,604)
Redemptions of financial assets at amortized cost 8,326,666 8,219,792 6,403,372
Dividends received from investments 445,602 477,568 411,369
Acquisition of investments in associates (2,486) (2,433) (7,267)
Capitalized leasing cost (335) (132) (690)
Proceeds from sale of investments in associates     2,645,914
Deconsolidation of entities   (2,290)  
Discontinued operation     (17,570,390)
Net cash (used) provided in investing activities (3,141,873) 1,840,647 (13,012,475)
Cash flows from financing activities:      
Dividends paid to shareholders (728,181) (766,537) (414,267)
Dividends paid to non-controlling interest (667,330) (915,933) (615,177)
Issuance of debt securities 2,262,527 2,609,994 695,136
Payment of outstanding debt securities (1,758,387) (4,072,742) (7,837,898)
Leases (416,640) (391,667) (383,472)
Equity transaction (55,000)   (15,014)
Net cash used in financing activities (1,363,011) (3,536,885) (8,570,692)
Effect of foreign currency changes on cash and cash equivalents 2,123,593 (2,744,259) 3,588,921
Decrease in cash and cash equivalents from discontinued operations     (1,393,602)
(Decrease) increase in cash and cash equivalents (1,599,002) 1,565,004 (19,609,972)
Cash and cash equivalents at beginning of year 18,597,861 17,032,857 36,642,829
Cash and cash equivalents at end of year $ 16,998,859 $ 18,597,861 $ 17,032,857